KR20130083570A - A composition comprising an extract of rhus vernicifluastokes for the prevention and treatment of arthritis - Google Patents
A composition comprising an extract of rhus vernicifluastokes for the prevention and treatment of arthritis Download PDFInfo
- Publication number
- KR20130083570A KR20130083570A KR1020120004226A KR20120004226A KR20130083570A KR 20130083570 A KR20130083570 A KR 20130083570A KR 1020120004226 A KR1020120004226 A KR 1020120004226A KR 20120004226 A KR20120004226 A KR 20120004226A KR 20130083570 A KR20130083570 A KR 20130083570A
- Authority
- KR
- South Korea
- Prior art keywords
- molecular weight
- extract
- lacquer
- composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000284 extract Substances 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 244000044283 Toxicodendron succedaneum Species 0.000 title claims abstract description 15
- 230000002265 prevention Effects 0.000 title claims abstract description 14
- 206010003246 arthritis Diseases 0.000 title description 8
- 239000004922 lacquer Substances 0.000 claims abstract description 57
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 241000208225 Rhus Species 0.000 claims description 18
- 235000014220 Rhus chinensis Nutrition 0.000 claims description 18
- 239000013078 crystal Substances 0.000 claims description 15
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 239000005711 Benzoic acid Substances 0.000 claims description 8
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 8
- FNUPUYFWZXZMIE-UHFFFAOYSA-N Fustin Natural products O1C2=CC(O)=CC=C2C(=O)C(O)C1C1=CC=C(O)C(O)=C1 FNUPUYFWZXZMIE-UHFFFAOYSA-N 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 6
- AYMYWHCQALZEGT-ORCRQEGFSA-N butein Chemical compound OC1=CC(O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 AYMYWHCQALZEGT-ORCRQEGFSA-N 0.000 claims description 5
- OBWHQJYOOCRPST-UHFFFAOYSA-N 3,4',7-trihydroxyflavone Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=CC=C(O)C=C2O1 OBWHQJYOOCRPST-UHFFFAOYSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 4
- 229940074391 gallic acid Drugs 0.000 claims description 4
- 235000004515 gallic acid Nutrition 0.000 claims description 4
- VRTGGIJPIYOHGT-LSDHHAIUSA-N garbanzol Chemical compound C1([C@@H]2[C@H](C(C3=CC=C(O)C=C3O2)=O)O)=CC=C(O)C=C1 VRTGGIJPIYOHGT-LSDHHAIUSA-N 0.000 claims description 4
- VRTGGIJPIYOHGT-UHFFFAOYSA-N garbanzol Natural products O1C2=CC(O)=CC=C2C(=O)C(O)C1C1=CC=C(O)C=C1 VRTGGIJPIYOHGT-UHFFFAOYSA-N 0.000 claims description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 4
- 229960003512 nicotinic acid Drugs 0.000 claims description 4
- 235000001968 nicotinic acid Nutrition 0.000 claims description 4
- 239000011664 nicotinic acid Substances 0.000 claims description 4
- 229960001285 quercetin Drugs 0.000 claims description 4
- 235000005875 quercetin Nutrition 0.000 claims description 4
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 229940074360 caffeic acid Drugs 0.000 claims description 3
- 235000004883 caffeic acid Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 235000011990 fisetin Nutrition 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- FNUPUYFWZXZMIE-HUUCEWRRSA-N fustin Chemical compound C1([C@@H]2[C@@H](C(C3=CC=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 FNUPUYFWZXZMIE-HUUCEWRRSA-N 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims description 3
- 238000007598 dipping method Methods 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 claims 2
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 abstract description 11
- 230000003078 antioxidant effect Effects 0.000 abstract description 7
- 230000008929 regeneration Effects 0.000 abstract description 7
- 238000011069 regeneration method Methods 0.000 abstract description 7
- 230000030833 cell death Effects 0.000 abstract description 6
- 230000012010 growth Effects 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 5
- 235000013376 functional food Nutrition 0.000 abstract description 4
- 230000001629 suppression Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- 210000001612 chondrocyte Anatomy 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 8
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 229940124595 oriental medicine Drugs 0.000 description 4
- RMTXUPIIESNLPW-UHFFFAOYSA-N 1,2-dihydroxy-3-(pentadeca-8,11-dienyl)benzene Natural products CCCC=CCC=CCCCCCCCC1=CC=CC(O)=C1O RMTXUPIIESNLPW-UHFFFAOYSA-N 0.000 description 3
- QARRXYBJLBIVAK-UEMSJJPVSA-N 3-[(8e,11e)-pentadeca-8,11-dienyl]benzene-1,2-diol;3-[(8e,11e)-pentadeca-8,11,14-trienyl]benzene-1,2-diol;3-[(8e,11e,13e)-pentadeca-8,11,13-trienyl]benzene-1,2-diol;3-[(e)-pentadec-8-enyl]benzene-1,2-diol;3-pentadecylbenzene-1,2-diol Chemical compound CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O.CCCCCC\C=C\CCCCCCCC1=CC=CC(O)=C1O.CCC\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.C\C=C\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.OC1=CC=CC(CCCCCCC\C=C\C\C=C\CC=C)=C1O QARRXYBJLBIVAK-UEMSJJPVSA-N 0.000 description 3
- IYROWZYPEIMDDN-UHFFFAOYSA-N 3-n-pentadec-8,11,13-trienyl catechol Natural products CC=CC=CCC=CCCCCCCCC1=CC=CC(O)=C1O IYROWZYPEIMDDN-UHFFFAOYSA-N 0.000 description 3
- 102000016284 Aggrecans Human genes 0.000 description 3
- 108010067219 Aggrecans Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000000554 physical therapy Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- DQTMTQZSOJMZSF-UHFFFAOYSA-N urushiol Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000077 insect repellent Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- WGWLJXSPRAJHNT-UHFFFAOYSA-N OC=1C=C(C=CC1O)C=CC(=O)C1=C(C=C(C=C1)O)O.CCCC Chemical compound OC=1C=C(C=CC1O)C=CC(=O)C1=C(C=C(C=C1)O)O.CCCC WGWLJXSPRAJHNT-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000003811 acetone extraction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000000238 one-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 옻나무 (Rhus verniciflua Stokes) 추출물을 유효성분으로 함유하는 퇴행성 관절염의 예방 및 치료용 조성물에 관한 것으로, 옻나무 열수 추출물은 활성화된 세포의 생장과 재생 및 세포에서 연골생성에 효과가 있고, 세포독성 및 항산화 효과를 제공하며 세포 사멸억제 효과가 뛰어난 옻나무 추출물을 유효성분으로 함유하는 퇴행성 관절염의 예방 및 치료용 조성물 및 건강기능식품으로 유용하게 이용될 수 있다.The present invention relates to a composition for the prevention and treatment of degenerative arthritis containing Rhus verniciflua Stokes extract as an active ingredient, the lacquer hydrothermal extract is effective for the growth and regeneration of activated cells and the generation of cartilage in cells. It provides toxic and antioxidant effects and can be useful as a composition for the prevention and treatment of degenerative arthritis and health functional food containing lacquer extract with excellent cell death suppression effect as an active ingredient.
Description
본 발명은 옻나무 (Rhus verniciflua Stokes) 추출물을 유효성분으로 함유하는 퇴행성 관절염의 예방 및 치료용 조성물에 관한 것으로, 본 발명의 옻나무 추출물은 활성화된 세포의 생장과 재생 및 세포에서 연골생성에 효과가 있고, 세포독성 및 항산화 효과를 제공하며 세포 사멸억제 효과가 뛰어난 옻나무 추출물을 유효성분으로 함유하는 퇴행성 관절염의 예방 및 치료용 조성물을 제공하는데 있다.
The present invention relates to a composition for the prevention and treatment of degenerative arthritis containing Rhus verniciflua Stokes extract as an active ingredient, the lacquer extract of the present invention is effective in the growth and regeneration of activated cells and cartilage production in cells. It provides a cytotoxic and antioxidant effect, and provides a composition for the prevention and treatment of degenerative arthritis, which contains the lacquer extract excellent in inhibiting cell death as an active ingredient.
옻나무(Rhus verniciflua Stokes)는 옻나무과 (Anacardiaceae)에 속하는 낙엽 활엽소교목으로 중앙아시아 고원지대 및 히말라야 지방이 원산지로 알려져 있으며, 현재 전세계적으로 열대지방을 중심으로 한 아열대지방과 온대지방에 널리 분포하고 있고, 낙엽 또는 상록성으로 대부분이 교목 또는 관목성이나 일부는 덩굴성으로 자라는 것으로 알려져 있다(Barkley Fred Alexander., Ann. of the Missouri Bot.Garden., 24(3), pp265-500, 1937).Rhus verniciflua Stokes is a deciduous broad-leaved arborescent belonging to the family Anacardiaceae, and is known for its origin in the Central Asian Highlands and the Himalayas, and is widely distributed in the subtropical and temperate regions of the world. Deciduous or evergreen, mostly arborescent or shrub but partly vine-grown (Barkley Fred Alexander., Ann. Of the Missouri Bot. Garden., 24 (3), pp 265-500, 1937).
구체적으로 옻나무의 줄기는 곧게 올라가며 잎은 기이하게 생겼으며 가시가 나있고 여러 잎이 하나의 잎으로 공생하고 잎의 끝과 끝을 포함하여 25∼40cm정도이다.Specifically, the stem of the sumac is straight up, the leaves are bizarre, spiny, and many leaves symbiotic with one leaf, including 25 ~ 40cm including the tip and the end of the leaf.
작은 잎은 7∼20cm, 너비 3∼6cm의 알 모양 또는 둥근 알 모양으로 9∼13개이다. 꽃은 암,수로서 연한 녹황색으로 피며 뾰족하며 둥근 모양으로 꽃이 피며 밑으로 쳐지고 길이 15∼25cm이다. 열매는 지름 6∼8mm의 편구형 열매로 10월에 연한 황색으로 익는다.Small leaf is 7-20cm, 3-6cm wide egg shape or round egg shape 9-13. Flowers are male and female, light greenish yellow, pointed, round, flowering, splattered, 15-25cm long. Fruits are spherical, 6-8 mm in diameter, ripen in light yellow in October.
옻나무의 수액을 옻이라 하는데, 옻은 칠공예 및 산업용의 천연도료로 이용되고 있으며 한방에서는 구충, 복통, 통경, 변비, 어혈, 여인 경맥불통에 건칠을 이용해 왔으며, 내약품성이 있어 비행기, 선박 빛 해저광케이블 증에 사용되는 특수 외장도료로서 활용될 수 있다. 더욱이 동양에서는 예로부터 약용으로 사용되어 왔고, 한의학에서는 내과종양치료제 및 여성의 생리기 이상, 위장약, 구충제, 혈액 순환 및 노화방지의 민간요법 등에 이를 이용하는 처방이 전래되고 있다(Hota, M. 1989. 세계 유용식물사전, 평범사(일본) 910-2). 특히 한국에서는 몸 보신용 또는 약용으로 옻나무를 옻닭, 옻오리 등에 이용하여 왔다(신약, 김일훈 저, 발행처:나무, 1986). 그러나 옻에 대한 감수성이 예민한 사람에게는 아주 적은 옻과의 접촉에 의하여 피부염, 가려움증을 일으키는 경우가 있어 대부분의 사람들이 옻에 대한 접촉을 꺼리는 경향이 있으며 실제 옻에 예민한 반응을 보이지 않는 사람은 10명 중 3~4명 정도이다.The sap of lacquer tree is called lacquer, and lacquer is used as lacquer for painting and industrial purposes. In oriental medicine, it has been used for insect repellent, abdominal pain, tuberculosis, constipation, fish blood, woman meridian. It can be used as a special exterior paint used for submarine fiber optic cables. Moreover, oriental medicine has been used for a long time, and oriental medicine has been introduced in the treatment of internal tumors and women's menstrual disorders, gastrointestinal drugs, repellents, blood circulation and anti-aging folk remedies (Hota, M. 1989). World Useful Plant Dictionary, Common History (Japan) 910-2). In particular, in Korea, lacquer trees have been used for lacquer chickens, lacquer ducks, etc. (New Testament, Il-hoon Kim, Publisher: Namu, 1986). However, for those who are sensitive to lacquer, dermatitis and itching may be caused by very little contact with lacquer, and most people tend to be reluctant to make contact with lacquer. About 3 to 4 of them.
이마저도 일시적으로 옻에 알러지를 보인 이후에는 그 예민성이 극도로 높아져 극미량의 접촉에 의해서도 피부염 증세를 보이게 되는 경우가 많다.Even after allergic to lacquer temporarily, the sensitivity is extremely high, and even a small amount of contact can cause symptoms of dermatitis.
옻나무 수액(옻칠액)의 주요성분은 우루시올(Urushiol)이며, 주용도는 칠공예에 사용되며 성상은 진갈색 액체로서 유기용매에 잘 용해된다. 화학적 구조는 곁사슬의 탄소수가 15~17개가 주종을 이루며 불포화 결합이 다수 존재한다. The main component of the lacquer sap (Lac lacquer) is urushiol (Urushiol), its main purpose is used in lacquerware, and its appearance is a dark brown liquid, which dissolves well in organic solvents. The chemical structure is mainly composed of 15 to 17 carbon atoms in the side chain, and many unsaturated bonds exist.
옻의 주된 약리작용은 항암, 항산화, 숙취해소 작용 등이 알려져 있으며(식품과학회지, 31, 1997, 238-245), 위장병, 심장병, 관절염, 고혈압, 당뇨, 중풍, 만성피로 등에 효능이 있는 것으로 알려져 있다. 이러한 다양한 약리작용이 있음에도 불구하고 상업적으로 널리 이용되지 못한 것은 인체에 대한 알러지 유발 성질 때문인 것으로 알려져 있다.The main pharmacological effects of lacquer are known to be anti-cancer, antioxidant, hangover-relieving action (Food Science Journal, 31, 1997, 238-245), gastrointestinal disease, heart disease, arthritis, high blood pressure, diabetes, stroke, chronic fatigue, etc. Known. Despite these various pharmacological actions, it has been known that the commercial use is not due to allergic properties to the human body.
최근에 이루어진 연구결과를 보면 옻칠액의 주성분이며 알레르기를 유발하는 옻산성분이 강한 항암, 항산화 및 항균활성이 있는 것으로 보고되었으며, 옻나무의 수피 및 목부에서 추출된 flavonoids성분이 혈관형성 억제작용을 나타내어 암세포의 증식 및 전이를 억제하고 암세포를 정상세포로의 분화를 유도하는 항암효과가 확인되었고 또한 항산화, 숙취해소 및 위염억제효과도 있다는 것이 밝혀졌다. 칠액이 固化된 것을 분쇄하여 분말로 만든 것을 乾漆이라 하는데 한방 및 민간에서는 혈액촉진, 위산과다, 생리통, 어혈제거, 펀도선염, 구충제로 쓰인다.According to the recent research results, lacquer solution is the main ingredient of lacquer liquid and allergic lactate component has strong anti-cancer, antioxidant and antimicrobial activity, and the flavonoids extracted from the bark and the neck of lacquer tree show the inhibitory effect on angiogenesis. The anti-cancer effect of inhibiting the proliferation and metastasis of cancer cells and inducing the differentiation of cancer cells into normal cells was also confirmed. It is a powder made by crushing the lactose into powder and it is used in oriental medicine and private medicine to promote blood, excessive acid, dysmenorrhea, fish blood removal, fundominitis, and insect repellent.
옻나무는 지금까지는 그 섭취에 있어 통상적으로 닭 또는 토끼, 오리 등과 같이 가열하여 얻어지는 탕의 형태가 주를 이루고 있으며 이 경우 옻나무에 존재하는 알러지 유발성분인 우루시올로 인하여 섭취 후 알러지가 발생하는 등의 부작용이 있어 왔으며 이를 단순히 몸에 좋을 것이라는 이유로 참으면서 섭취하여 왔다. Until now, lacquer tree is mainly in the form of hot water obtained by heating such as chicken, rabbit, duck, etc. In this case, allergy occurs after ingestion due to urushiol, an allergen that is present in the lacquer tree. There has been and has been eating it simply because it is good for the body.
옻나무가 가진 약리적 효능을 그대로 가지면서 부작용 없이 섭취할 수 있는 방법의 개발은 국민의 건강회복 및 건강증진을 위하여 요구되어 왔으며 일부 기술이 개발되고 있다. 본 발명자 및 출원인은 지금까지 옻나무 관련 연구를 지속적으로 추진하여 왔다.Development of a method that can be ingested without side effects while maintaining the pharmacological effects of sumac has been required for the public's health recovery and health promotion, and some technologies have been developed. The present inventors and applicants continue to push forward the research of the sumac until now.
일반적으로, 퇴행성 관절염은 관절 질환 중에서 가장 많이 발생하는 관절염으로 뼈의 관절면을 감싸고 있는 관절 연골이 마모되어 연골 밑의 뼈가 노출되고, 관절 주변의 활액막에 염증이 생겨서 통증과 변형이 발생하는 질환이다.In general, degenerative arthritis is one of the most common arthritis diseases, in which articular cartilage surrounding the joint surface of the bone is worn and bones under the cartilage are exposed, and inflammation and synovial membrane around the joint cause pain and deformation. to be.
관절 연골의 손상을 가져오게 되는 원인으로는 체중 과다, 관절의 외상, 주위 뼈의 질환, 근육의 약화, 관절의 신경 손상, 이외에 유전적인 소인에 의해 발생할 수도 있으며, 관절은 고관절, 슬관절, 요추 등에 많이 발생하며 이외에 손가락이나 발가락 등에도 발생할 수 있다. The causes of joint cartilage damage may be caused by overweight, trauma of the joint, disease of the surrounding bone, muscle weakness, nerve damage of the joint, or other genetic predisposition. It also occurs a lot and can also occur on fingers or toes.
치료방법으로 약물요법으로는 단순히 통증을 완화하기 위한 비마약성 진통제로 아세토아미노펜, 트라마돌를 사용하기도 하며 관절이 붓고 심한 경우에는 비스테로이드성 항소염제로 아스피린. 이부프로펜, 인도메타신, 나프록신 등을 사용하여 아세토아미노펜으로 조절되지 않거나 염증성 퇴행성 관절염의 염증을 줄이고자 할 때 사용하기도 하고, 피부에 직접 발라 효과를 얻는 연고형 진통소염제 또는 트라스트, 케토톱, 류마스탑과 같은 패취형 진통염제를 사용하고 있으며, 약물치료로 반응하지 않는 퇴행성 관절염에 부신피질 호르몬, 하이알루로난을 관절강내 주사 요법도 사용한다.As a treatment, acetoaminophen or tramadol may be used as a non-narcotic analgesic to simply relieve pain. Aspirin may be used as a nonsteroidal anti-inflammatory agent in swollen joints. Ointments such as ibuprofen, indomethacin, and naproxine, which are not controlled with acetoaminophen or are used to reduce inflammation of inflammatory degenerative arthritis, are used as ointment analgesic agents or trasts, ketotops, rheumatoids that are applied directly to the skin. It uses patch-type painkillers such as Stop, and intraarticular injection therapy with corticosteroids and hyaluronan for degenerative arthritis that does not respond to medication.
최근에는 연골 성분 제제(글루코사민, 콘드로이틴)가 치료제로 대두되고 있는데, 유럽에서는 약품으로 분류되어 실제 환자들에게 사용되고 있습니다. In recent years, cartilage components (glucosamine and chondroitin) have emerged as therapeutic agents. In Europe, they are classified as drugs and used in actual patients.
약물치료와 더불어 물리치료를 시행하는 것은 증상 완화에 큰 도움이 되며, 관절 주위의 근육을 강화시키는 것은 증상을 완화시킬 뿐만 아니라 골관절염의 악화를 방지하는 데에도 매우 중요합니다. 따라서 약물 복용에만 의존하는 것보다는 물리치료를 병행해야만 최선의 효과를 기대할 수 있습니다. 초기에는 전문가의 도움으로 물리치료를 받고 스스로 할 수 있는 방법을 익혀서 나중에는 일상생활에서도 자율적으로 근육 강화운동을 해야 합니다. Physiotherapy, along with medications, is very helpful in relieving your symptoms, and strengthening the muscles around your joints is important not only to relieve your symptoms, but also to prevent exacerbations of osteoarthritis. Therefore, rather than relying solely on medications, you can expect the best effect only with physical therapy. In the early stages, you need to get physical therapy with the help of a specialist and learn how to do it yourself.
이상의 방법으로도 큰 효과를 거두지 못하면 수술을 고려하게 되는데 수술은 관절경을 이용하기도 하고 비교적 활동적인 사람에게는 뼈의 모양을 올바르게 해 주는 절골술을 시행하기도 합니다. 이 밖에 관절 연골을 이식해 줄 수도 있지만 이식술은 국소적인 영역에 이상이 있을 때만 시행하는 것이기 때문에 연골의 마모가 넓게 퍼져 있는 퇴행성 관절염에는 해당이 되지 않는 경우가 많습니다. 관절염이 매우 심해서 여타의 방법으로도 낫지 않거나 나을 가능성이 없을 때는 인공관절 성형술을 시행합니다.If the above methods do not have a great effect, surgery will be considered. Surgery may be done using arthroscopy or osteotomy, which allows bones to be shaped correctly for people who are relatively active. In addition, articular cartilage can be transplanted, but transplantation is performed only when there is an abnormality in the local area. Therefore, this is not the case for degenerative arthritis, in which cartilage wear is widespread. If arthritis is so severe that other options do not heal or are likely to heal, arthroplasty is performed.
따라서, 본 발명자는 상기 옻나무 추출물의 퇴행성 관절염 예방 및 치료 효능 효과를 연구하던 중 옻나무 추출물의 면역억제 효과, 활막세포 활성억제 효과, 소염 효과 및 관절염 동물모델에서 예방 및 치료 효과를 약리학적으로 관찰한 결과, 퇴행성 관절염 예방 및 치료 효과가 우수함을 확인하여 본 발명을 완성하였다.
Therefore, the present inventors pharmacologically observed the immunosuppressive effect, synovial cell activity suppression effect, anti-inflammatory effect and preventive and therapeutic effects in arthritis animal models of the lacquer extract while studying the efficacy of preventing and treating degenerative arthritis of the lacquer extract. As a result, it was confirmed that the degenerative arthritis prevention and treatment effect is excellent to complete the present invention.
[관련기술문헌][Related Technical Literature]
1. 인삼노두 추출물을 함유하는 관절염의 예방 또는 치료용 약학적 조성물(특허출원번호 10-2004-0084427)
1. A pharmaceutical composition for preventing or treating arthritis containing ginseng extract (patent application No. 10-2004-0084427)
본 발명은 본 발명의 옻나무 추출물은 활성화된 세포의 생장과 재생 및 세포에서 연골생성에 효과가 있고, 세포독성 및 항산화 효과를 제공하며 세포 사멸억제 효과가 뛰어난 옻나무 추출물을 유효성분으로 함유하는 퇴행성 관절염의 예방 및 치료용조성물에 관한 것이다.In the present invention, the lacquer extract of the present invention is effective in the growth and regeneration of activated cells and cartilage production in cells, provides cytotoxicity and antioxidant effect, and degenerative arthritis containing lacquer extract with excellent cell death suppression effect as an active ingredient. It relates to a composition for the prevention and treatment of.
본 발명의 목적은 옻나무 (Rhus verniciflua Stokes) 추출물을 유효성분으로 함유하는 퇴행성 관절염의 예방 및 치료용 약학 조성물 및 건강기능식품을 제공하는 것이다.
An object of the present invention is to provide a pharmaceutical composition and health functional food for the prevention and treatment of degenerative arthritis containing the extract of Rhus verniciflua Stokes as an active ingredient.
상기의 목적을 달성하기 위한 본 발명의 제 1 특징에 따르면, 옻나무를 열수추출 및 C1-4 저급 알코올, 주정 알코올, 아세톤 추출 또는 열수추출 후 C1-4 저급 알코올, 주정 알코올 담금으로 얻어진 옻나무 추출물을 유효성분으로 포함하는 퇴행성 관절염의 예방 및 치료용 조성물을 제공한다.According to a first aspect of the present invention for achieving the above object, the lacquer extract obtained by dipping C1-4 lower alcohol, ethanol alcohol after hot water extraction and C1-4 lower alcohol, alcohol alcohol, acetone extraction or hot water extraction It provides a composition for the prevention and treatment of degenerative arthritis comprising as an active ingredient.
상기의 목적을 달성하기 위한 본 발명의 제 2 특징에 따르면, 옻나무 열수 추출물로 분획된 C15H12O6(분자량 288)이며 백색의 결정체를 갖는 푸스틴(3,3',4',7-tetrahydroxyflavanone), C15H10O6(분자량 286)이며 황색의 결정체를 갖는 피세틴(Fisetin; 3,3',4',7-Tetrahydroxyflavone), C15H10O5(분자량 272)이며 진한 오렌지색의 결정체를 갖는 설푸레틴(Sulfuretin; 3',4',6'-Trihydroxyaurone), C15H12O5(분자량 272)이며 오렌지색의 결정체를 갖는 부테인(Butein; 2',3,4,4'-Tetrahydroxychalcone), C15H12O5(분자량 272)인 Garbanzol, C15H10O7(분자량 302)인 Quercetin, C15H10O5(분자량 270)인 5-deoxykaempferol, C6H6O2(분자량 110)인 Resorcino, C7H6O4(분자량 154)인 3,4-Benzoic acid, C7H6O4(분자량 154)인 2,4-Benzoic acid, C7H6O5(분자량 170)인 Gallic acid, C9H8O4(분자량 180)인 Caffeic acid, C9H11O4N5(분자량 253)인 Adenosin, C6H5O2N(분자량 123)인 Niacin의 단일성분물질을 함유하는 퇴행성 관절염의 예방 및 치료용 조성물을 제공한다.According to a second aspect of the present invention for achieving the above object, Fustine (3,3 ', 4', 7) having C 15 H 12 O 6 (molecular weight 288) and white crystals fractionated with Sumac hot water extract -tetrahydroxyflavanone), C 15 H 10 O 6 (molecular weight 286), yellow crystals, fisetin (3,3 ', 4', 7-Tetrahydroxyflavone), C 15 H 10 O 5 (molecular weight 272), thick Sulphurtin with orange crystals (3 ', 4', 6'-Trihydroxyaurone), C 15 H 12 O 5 (molecular weight 272) and orange crystals Butane (2 ', 3,4, 4'-Tetrahydroxychalcone), Garbanzol with C 15 H 12 O 5 (molecular weight 272), Quercetin with C 15 H 10 O 7 (molecular weight 302), 5-deoxykaempferol with C 15 H 10 O 5 (molecular weight 270), C 6 H 6 O 2 (molecular weight 110) Resorcino, C 7 H 6 O 4 (molecular weight 154) 3,4-Benzoic acid, C 7 H 6 O 4 (molecular weight 154) 2,4-Benzoic acid, C 7 H 6 Gallic acid with O 5 (molecular weight 170), Caffeic acid with C 9 H 8 O 4 (molecular weight 180), C 9 H 11 O 4 N 5 (molecular weight 253) provides a composition for the prevention and treatment of degenerative arthritis containing a single component of Adenosin, C 6 H 5 O 2 N (molecular weight 123) Niacin.
이때, 본 발명의 부가적인 특징에 따르면, 상기 세포의 생장과 재생에 옻나무 추출물 300ug/ml 농도와 유전자 발현 조절에 옻나무 추출물 100ug/ml 농도로 설정되는 것이 바람직하다.At this time, according to an additional feature of the present invention, the growth and regeneration of the cell is preferably set to 300ug / ml concentration of the lacquer extract and 100ug / ml concentration of the lacquer extract to control gene expression.
또한, 통상의 제조 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탄액, 에멀젼, 시럽, 에어로졸의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화할 수 있다.It may also be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, oral formulations of aerosols, external preparations, suppositories and sterile injectable solutions according to conventional methods of preparation.
또한, 면역세포 및 활막세포의 증식을 억제하고, 세포독성 및 항산화 효과를 제공하며 세포 사멸억제 효과를 갖는 옻나무 추출물을 유효성분으로 함유하는 옻나무 추출물을 유효성분으로 함유하는 관절염의 개선용 건강기능식품을 제공한다.
In addition, health functional foods for improving arthritis, which contains the lacquer extract as an active ingredient, which suppresses the proliferation of immune cells and synovial cells, provides cytotoxic and antioxidant effects, and has the effect of inhibiting cell death as an active ingredient. To provide.
본 발명에 의한 옻나무 추출물을 유효성분으로 함유하는 퇴행성 관절염의 예방 및 치료용 조성물은 세포에서 연골 생성에 관한 유전자의 발현에 따른 세포생장과 재생에 옻나무 추출물이 효과가 있다.In the composition for the prevention and treatment of degenerative arthritis containing the lacquer extract according to the present invention as an active ingredient, the lacquer extract has an effect on cell growth and regeneration according to the expression of genes related to cartilage production in cells.
또한, 본 발명의 적용은 상기 실시 예에 언급된 사항들에 한정되는 것이 아니라 옻나무 추출물을 산제, 과립제, 정제, 캡슐제, 현탄액, 에멀젼, 시럽, 에어로졸의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 다양하게 제형화할 수 있으며, 통상의 건강식품의 담체와 혼합하여 건강기능식품으로 제형화할 수 있다.
In addition, the application of the present invention is not limited to the matters mentioned in the above examples, the lacquer extract powder, granules, tablets, capsules, suspensions, emulsions, syrups, oral formulations of aerosols, external preparations, suppositories and sterilization It can be formulated in various forms in the form of injectable solutions, and can be formulated as a health functional food by mixing with a carrier of a conventional health food.
도 1은 본 발명에 따른 옻나무 열수추출물의 분말을 제조하는 공정을 도시한 흐름도
도 2a 내지 도 2b는 본 발명에 따른 옻나무 추출물의 분획된 단일물질의 화학구조식
도 3은 본 발명에 따른 옻나무 추출물의 MTT assay ANOVA에 의해 결정된 연골세포의 Multiple Range test에 옻나무 추출물의 세포독성의 결과를 도시한 그래프.
도 4는 본 발명에 따른 옻나무 추출물에서 H2O2에 의해 유도된 세포사멸로부터 연골(chondrocytes)를 보호 또는 억제하는 효과를 도시한 그래프.
도 5는 본 발명에 따른 옻나무 추출물의 관절세포의 isotope labeled sodium sulfate의 세포내 proteoglycan 합성을 위한 incorporation에 미치는 옻나무 열수추출물의 효과의 연골세포 활성평가를 도시한 그래프.
도 6 내지 도 7는 본 발명에 따른 옻나무 추출물의 Real Time PCR을 수행한 결과 Collagen 및 Aggrecan의 생성정도가 증가하는 것을 도시한 그래프.
도 8 내지 도 9은 본 발명에 따른 옻나무 추출물이 MMPs 측정결과 MMPs의 감소 상태를 나타낸 그래프.1 is a flow chart showing a process for producing a powder of the sumac hot water extract according to the present invention.
2a to 2b is a chemical structural formula of the fractionated single substance of the lacquer extract according to the present invention
Figure 3 is a graph showing the results of cytotoxicity of the lacquer extract in the Multiple Range test of chondrocytes determined by MTT assay ANOVA of the lacquer extract according to the present invention.
Figure 4 is a graph showing the effect of protecting or inhibiting chondrocytes from apoptosis induced by H 2 O 2 in the sumac extract according to the present invention.
Figure 5 is a graph showing the evaluation of chondrocyte activity of the effect of lacquer hot water extract on the incorporation for intracellular proteoglycan synthesis of isotope labeled sodium sulfate of the lacquer extract of the lacquer tree extract according to the present invention.
6 to 7 are graphs showing that the production of Collagen and Aggrecan increases as a result of performing Real Time PCR of the extract of Sumac according to the present invention.
8 to 9 is a graph showing the reduced state of the MMPs of the lacquer extract according to the present invention MMPs measurement results.
이하, 첨부된 도면을 참조하여 본 발명의 바람직한 실시예를 상세히 설명한다.Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings.
본 발명에 따른 옻나무 추출물은 통상의 추출방법에 의해 추출된 옻나무 추출물을 사용한다.The sumac extract according to the present invention uses the sumac extract extracted by a conventional extraction method.
이하, 본 발명은 옻나무 열수 추출물을 시료로 하여 male SD rat으로부터 분리한 chondrocytes에 대한 효과를 1) 세포의 생장과 재생, 2) 세포에서 연골생성에 관여하는 유전자의 발현의 두가지 측면에서 검토한 결과 세포생장과 재생에는 옻나무 열수 추출물 300ug/ml 농도에서 효과가 있는 것으로 선정되었고 유전자 발현 조절에는 추출물의 효과는 100ug/ml 농도에서 조건에 맞는 것으로 결정하여 그에 따른 관찰결과를 도출하도록 실험 및 결과를 제시하고자 한다.
Hereinafter, the present invention examines the effects on chondrocytes isolated from male SD rats using the lacquer hydrothermal extract as a sample in two aspects: 1) cell growth and regeneration, and 2) expression of genes involved in cartilage production in cells. The cell growth and regeneration were selected to be effective at 300ug / ml concentration of the lacquer hot water extract, and the effect of the extract was adjusted to the conditions at 100ug / ml concentration to control gene expression. I would like to.
1. 실험방법1. Experimental Method
1.1 옻나무로부터 물질 분리1.1 Separation of substances from sumac
(단계 1) 옻나무 추출물 분말의 제조(Step 1) Preparation of Sumac Extract Powder
도 1에 도시된 바와 같이 옻나무추출분말을 얻기 위해서는, 옻나무의 목재부를 절단하여 그늘에서 1 주일 내지 3 개월 정도 건조한 후, 5cm내지 15cm 길이로 절단하여 목재칩이나 톱밥으로 제조하여 사용한다. 옻나무 무게 10배수의 음용수을 넣고 80 내지 120℃에서 4시간 동안 2회 추출한다.As shown in Figure 1, in order to obtain the lacquer extract powder, after cutting the wood part of the lacquer and dried for about one week to three months in the shade, it is cut into 5cm to 15cm length and used to produce wood chips or sawdust. Put drinking water of 10 times the weight of sumac and extract twice at 80 to 120 ℃ for 4 hours.
또는 용매로서 메탄올, 주정알코올 등을 동량 가하여 20 내지 60℃ 온도로 추출한다. 아세톤을 동량 가하여 35℃에서 45℃의 수조에서 1일 내지 10일 방치하거나 실내에서 10일 내지 30일 동안 방치하여 노란색의 추출액을 얻을 수 있다.Alternatively, methanol, spirit alcohol and the like are added in the same amount as a solvent and extracted at a temperature of 20 to 60 ° C. The same amount of acetone may be added and left for 1 to 10 days in a water bath at 45 ° C. at 45 ° C. or for 10 to 30 days in a room to obtain a yellow extract.
상기와 같이 옻나무를 추출하여 얻어진 추출물에 C1-4 저급 알코올, 주정 알코올 담금을 하여 얻어진 주정 알코올 가용물을 열풍건조, 동결건조 또는 진공건조 방법으로 건조한다.The alcohol obtained by immersing the C1-4 lower alcohol and alcohol alcohol in the extract obtained by extracting the lacquer as described above is dried by hot air drying, freeze drying or vacuum drying.
이때, C1-4 저급 알코올은 메탄올, 에탄올을 주정의 형태로 사용하거나, 주정알코올로 사용할 수도 있다.In this case, the C1-4 lower alcohol may be used as methanol, ethanol in the form of alcohol, or alcohol alcohol.
상기에서 옻나무추출분말을 추출과정에서 옻나무의 목재부를 절단하여 그늘에서 1 개월 정도 건조하거나, 10cm 길이로 절단하여 사용할 수도 있으며, 옻나무 무게 10배수의 음용수을 넣고 100℃에서 4시간동안 2회 추출할 수도 있다. In the extraction process of the lacquer extract powder, the wood part of the lacquer is cut in the extraction process and dried for about 1 month in the shade, or it may be cut and used for 10 cm in length. have.
또한, 아세톤을 동량 가하여 40℃의 수조에서 5일 동안 방치하거나 실내에서 10일 내지 30일 동안 방치하여 노란색의 추출액을 얻을 수도 있다.
In addition, the same amount of acetone may be left for 5 days in a water bath at 40 ℃ or left for 10 to 30 days in the room to obtain a yellow extract.
(단계 2) 옻나무의 물질 분리 과정(Step 2) Material Separation Process of Sumac
상기 (단계 1)에서 얻은 옻나무의 추출물을 헥산으로 분획하여 비극성 부분을 분리하고, 남은 수층을 에틸아세테이트로 분획하여 감압 농축한다. 이렇게 극성별로 나누어진 헥산층, 에틸아세테이트층, 물층의 분획들을 silica gel로 세 분획 하고 다시 여러 컬럼 크로마토그래피를 이용하여 각각의 세 분획에서 계속하여 유효성분들을 분리한다.The extract of the lacquer tree obtained in the above (step 1) is partitioned with hexane to separate the nonpolar portion, and the remaining aqueous layer is partitioned with ethyl acetate and concentrated under reduced pressure. The hexane layer, ethyl acetate layer, and water layer partitioned by polarity were separated into three fractions by silica gel, and then separated by effective column chromatography using several column chromatography.
분획 및 물질의 분리는 silica gel 뿐 아니라, sephadex LH-20, ODS-A, diol, preparative MPLC, 또는 preparative HPLC 등의 다양한 크로마토그래피법을 이용하여 시행하였다.Separation of fractions and materials was carried out using various chromatographic methods such as sephadex LH-20, ODS-A, diol, preparative MPLC, or preparative HPLC as well as silica gel.
본 발명에 따른 옻나무 열수추출물을 3가지 분획으로 나누고 옻나무의 추출물을 극성에 따라 분획하고 각각의 분획을 silica gel을 포함한 여러 가지 column을 사용하여 분리를 시도하여 1D NMR과 2D NMR 방법을 이용하여 구조를 동정하고 LC/MS, UV, IR과 같은 최신 기기를 사용하여 14종의 단일 물질의 구조 확인을 완료하였다. The lacquer hot water extract according to the present invention is divided into three fractions, and the extract of the lacquer tree is partitioned according to the polarity, and each fraction is separated by using various columns including silica gel, using 1D NMR and 2D NMR methods. Was identified and structural confirmation of 14 single materials was completed using modern instruments such as LC / MS, UV, IR.
상기의 절차에 의해 분획된 14종의 단일물질은 첨부된 도 2a 내지 도 2b에서 제시된 화학구조식을 가지며 각각의 분자식은 C15H12O6(분자량 288)이며, 백색의 결정체를 갖는 푸스틴(3,3',4',7-tetrahydroxyflavanone), C15H10O6(분자량 286)이며 황색의 결정체를 갖는 피세틴(Fisetin; 3,3',4',7-Tetrahydroxyflavone), C15H10O5(분자량 272)이며 진한 오렌지색의 결정체를 갖는 설푸레틴(Sulfuretin; 3',4',6'-Trihydroxyaurone), C15H12O5(분자량 272)이며 오렌지색의 결정체를 갖는 부테인(Butein; 2',3,4,4'-Tetrahydroxychalcone), C15H12O5(분자량 272)인 Garbanzol, C15H10O7(분자량 302)인 Quercetin, C15H10O5(분자량 270)인 5-deoxykaempferol, C6H6O2(분자량 110)인 Resorcino, C7H6O4(분자량 154)인 3,4-Benzoic acid, C7H6O4(분자량 154)인 2,4-Benzoic acid, C7H6O5(분자량 170)인 Gallic acid, C9H8O4(분자량 180)인 Caffeic acid, C9H11O4N5(분자량 253)인 Adenosin, C6H5O2N(분자량 123)인 Niacin 등이 포함되어 있다.
The 14 monomaterials fractionated by the above procedure have the chemical formulas shown in FIGS. 2A-2B and each molecular formula is C 15 H 12 O 6 (molecular weight 288), with fustine having white crystals ( 3,3 ', 4', 7-tetrahydroxyflavanone), C 15 H 10 O 6 (molecular weight 286) and yellow crystals of fiscetin (Fisetin; 3,3 ', 4', 7-Tetrahydroxyflavone), C 15 H Sulphurtin (3 ', 4', 6'-Trihydroxyaurone) with 10 O 5 (molecular weight 272) and dark orange crystals, butane with C 15 H 12 O 5 (molecular weight 272) and orange crystals Butein; 2 ', 3,4,4'-Tetrahydroxychalcone), Garbanzol with C 15 H 12 O 5 (molecular weight 272), Quercetin with C 15 H 10 O 7 (molecular weight 302), C 15 H 10 O 5 (molecular weight 270 ) 5-deoxykaempferol, C 6 H 6 O 2 (molecular weight 110), C 7 H 6 O 4 (molecular weight 154) 3,4-Benzoic acid, C 7 H 6 O 4 (molecular weight 154) 2, 4-Benzoic acid, C 7 H 6 O 5 (molecular weight 170) Gallic acid, C 9 H 8 O 4 (molecular weight 180) affeic acid, Adenosin with C 9 H 11 O 4 N 5 (molecular weight 253) and Niacin with C 6 H 5 O 2 N (molecular weight 123).
1.2 재료 및 방법1.2 Materials and Methods
Table 1. 주요 시약 및 재료
Table 1. Key Reagents and Materials
1.3 연골(Chondrocytes) 분리 및 배양1.3 Isolation and Culture of Chondrocytes
실험을 위한 chondrocytes는 rat의 primary culture를 통해서 얻었고, primary culture의 진행은 다음과 같은 과정으로 진행하였다.The experimental chondrocytes were obtained from rat primary culture, and the primary culture proceeded as follows.
연골 채취를 위한 실험동물은 4~6주령 무게 약 180-200g 정도의 male Sprague-Dawley rat을 경추탈구 후에 70% 알코올로 피부를 소독하여 절개한 후, 관절연골을 2~3mm정도 크기로 채취하였다. The experimental animals for cartilage were collected by disinfecting the skin with 70% alcohol after cervical dislocation after male Sprague-Dawley rats weighing about 180-200g weighing 4 to 6 weeks. .
채취한 연골조직은 phosphate buffer saline(calcium & magnesium free, Hyclone SH30256.01) 용액에서 보관하여 clean bench로 옮겨 0.1% EDTA-CDMF(calcium magnesium free, Sigma E5134)용액에 30분씩 2회 넣어 incubation 시켰다(37℃, 5% CO2). 0.25% trypsin으로 1시간 incubation(37℃, 5% CO2) 시킨 후, 2mg/ml collagenase type I(Sigma, C0130)에서 흔들면서 overnignt시켰다. 이렇게 해서 얻어진 세포 부유액을 100um pore size cell strainer(BD Falcon, 352360, USA)에 여과한 후 1,600rpm으로 10분간 원심분리하여 원심분리된 세포를 Hank's balanced salt solution(Hyclone SH30031.01)으로 3회 세척한 후 연골세포를 얻었다. 얻어진 세포는 10% FBS(Fetal Bovine Serum, Hyclone, SH30396.03)와 DMEM(Hyclone, SH30243.01)에 1% penicillin-Streptomycin (Hyclone, SV30010)와 1% L-glutamine(Hyclone, SH30034.01) 그리고 0.1% Gentamycin sulfate(Lonza 17-518Z, USA)을 첨가하여 75T flask에서 배양하였다.
The collected cartilage tissue was stored in phosphate buffer saline (calcium & magnesium free, Hyclone SH30256.01) solution, transferred to a clean bench, and incubated twice with 0.1% EDTA-CDMF (calcium magnesium free, Sigma E5134) solution for 30 minutes. 37 ° C., 5% CO 2). Incubation with 0.25% trypsin for 1 hour (37 ° C., 5% CO 2) was followed by overnignt with shaking at 2 mg / ml collagenase type I (Sigma, C0130). The cell suspension thus obtained was filtered through a 100 μm pore size cell strainer (BD Falcon, 352360, USA) and centrifuged at 1,600 rpm for 10 minutes to wash the centrifuged cells three times with Hank's balanced salt solution (Hyclone SH30031.01). After that, chondrocytes were obtained. The cells obtained were 10% FBS (Fetal Bovine Serum, Hyclone, SH30396.03) and 1% penicillin-Streptomycin (Hyclone, SV30010) and 1% L-glutamine (Hyclone, SH30034.01) in DMEM (Hyclone, SH30243.01). And 0.1% Gentamycin sulfate (Lonza 17-518Z, USA) was added to incubate in a 75T flask.
1.4 In vitro 에서의 연골세포 활성 평가 1.4 Evaluation of chondrocyte activity in vitro
1) Cell Viability 측정1) Cell Viability Measurement
Primary culture를 통해 얻은 chondrocytes를 96well plate에 1x104 cells /well의 농도로 세포를 DMEM 배양액에 분주하여 4시간 동안 안정화시킨 후, 옻나무 추출물을 농도별로 처리하여 72시간(독성시험) 또는 4시간(H2O2 처리시) 동안 배양하였다.Chondrocytes obtained from primary cultures were stabilized for 4 hours by dispensing cells in DMEM culture at a concentration of 1x10 4 cells / well in 96well plate, and then treated with lacquer extract for 72 hours (toxicity test) or 4 hours (H Incubated for 2 0 2 ).
3-(4,5-methylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide(MTT) 시약을 20㎕처리하여 최대 4시간 37℃ incubator에서 배양한 후 배지와 MTT 시약을 제거하고, DMSO 시약 200㎕를 가하여 560nm에서 ELISA reader(VERSAMAXSL-20 Molecular Devices, Korea)를 이용하여 측정하였다. 3회의 측정으로 그에 대한 평균값과 표준 오차를 구하였다.
20 μl of 3- (4,5-methylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (MTT) reagent was incubated in a 37 ° C. incubator for up to 4 hours, then the medium and MTT reagent were removed. Μl was added and measured using an ELISA reader (VERSAMAXSL-20 Molecular Devices, Korea) at 560 nm. Three measurements yielded the mean and standard error.
2) 연골세포 활성 평가 - sodium sulfate incorporation2) Evaluation of chondrocyte activity-sodium sulfate incorporation
sodium sulfate는 proteoglycans의 생합성의 구성성분으로서 작용하게 된다. Sodium sulfate acts as a component of the biosynthesis of proteoglycans.
일반적으로 세포로의 흡수가 용이한 embryonic tissue에 처리하여 생합성 정도를 확인하는 방법이 많이 사용되어져 왔으나 본 실험에서는 생후 4주된 rat으로부터 아직 생장과정 중에 있는 chondrocytes 를 분리하여 사용함으로 세포로의 흡수를 용이하도록 하였다.
In general, many methods have been used to confirm the degree of biosynthesis by treating embryonic tissues that are easily absorbed into cells. However, in this experiment, chondrocytes that are still in the process of growth are separated from rats at 4 weeks of age. I did it.
1.5 in vitro에서 Collagen 및 MMPs 발현 확인1.5 Expression of Collagen and MMPs in Vitro
Rat의 연골로부터 채취한 chondrocyte 세포를 배양하여 세포독성실험을 바탕으로 샘플 및 H2O2 처리후, Quiagen RNeasy mini kit(USA, 74106)를 이용하여 mRNA를 추출하고 세포수준에서 유전자 발현정도를 측정하였다. Collagen 및MMPs는 Real Time PCR 방법으로 측정하였다. (Applied Biosystem, Step One Real-Time PCR System, USA)
After culturing chondrocyte cells collected from rat cartilage, based on cytotoxicity test, after treatment with samples and H 2 O 2 , mRNA was extracted using Quiagen RNeasy mini kit (USA, 74106) and the gene expression level was measured at the cellular level. It was. Collagen and MMPs were measured by Real Time PCR. (Applied Biosystem, Step One Real-Time PCR System, USA)
2. 실험 결과 1
2.
2.1 옻나무 추출물로부터 얻은 분획들의 in vitro 세포 사멸억제 효과 In vitro Cell Death Inhibitory Effects of Fractions Obtained from Sumac Extracts
본 발명에서 옻나무 추출물 분획을 얻어 primary cultured chondrocytes에서 in vitro 세포 사멸 억제효과를 규명하였다. In the present invention, the extract of the lacquer tree was investigated for the inhibition of in vitro cell death in primary cultured chondrocytes.
in vivo 실험 수행전에 일차적으로 in vitro 실험을 통해 가능한 농도를 우선 선정하기로 하였다. 옻나무 열수추출물 분획에서 세포독성은 도 3에 제시된 바와 같이 나타나지 않았다. Prior to performing in vivo experiments, it was decided to first select possible concentrations through in vitro experiments. Cytotoxicity in the lacquer hot water extract fraction was not shown as shown in FIG. 3.
즉, 도 1에서 MTT assay ANOVA에 의해 결정된 연골세포의 Multiple Range test에 의해 p < 0.05 값에서 옻나무 추출물의 세포독성의 유의성 확인한 결과 세포독성이 나타나지 않았다.
That is, as a result of confirming the significance of the cytotoxicity of the lacquer extract at p <0.05 value by the Multiple Range test of chondrocytes determined by MTT assay ANOVA in FIG. 1, there was no cytotoxicity.
또한, 도 4에서 도시된 바와 같이 옻나무 열수추출물에서 H2O2에 의해 유도된 세포사멸로부터 연골(chondrocytes)를 보호 또는 억제하는 효과가 샘플 농도 300μg/ml에서 가장 높게 나타났다.
In addition, as shown in FIG. 4, the effect of protecting or inhibiting chondrocytes from H 2 O 2 induced apoptosis in the lacquer hot water extract was the highest at the sample concentration of 300 μg / ml.
2.2 연골세포 활성 평가 - sodium sulfate incorporation2.2 Assessment of chondrocyte activity-sodium sulfate incorporation
실험의 결과에 따르면 전반적으로 세포로의 유입이 나타나는 것으로 보이지만 실험 처리군 사이에 유의적 변화가 크지는 않은 것으로 나타났다. The results of the experiment showed that the influx into the cell was generally observed, but there was no significant change between the experimental treatment groups.
그러나 옻나무 열수 추출물의 200ug/ml의 농도에서 가장 높은 세포 유입이 나타났으며 전반적으로 샘플의 효과가 있는 것으로 나타났다. However, the highest cell influx was observed at the concentration of 200 ug / ml of the lacquer hot water extract, and the overall effect of the sample was found.
즉, 도 5에 도시된 바와 같이 관절세포의 isotope labeled sodium sulfate (Na235SO4)의 세포내 proteoglycan 합성을 위한 incorporation에 미치는 옻나무 열수추출물의 효과는 ANOVA 수행 후 Multiple Range test에 의해 p < 0.05 값에서 유의성 확인할 수 있다.
That is, as shown in FIG. 5, the effect of the lacquer hot water extract on the incorporation for intracellular proteoglycan synthesis of isotope labeled sodium sulfate (Na235SO4) of articular cells was confirmed to be significant at p <0.05 value by ANOVA after Multiple Range test. Can be.
2.3 옻나무 열수 추출물로부터 얻은 분획들의 in vitro 효력시험(Real Time PCR)2.3 In Vitro Potency Test of Fractions Obtained from Hot Water Extract of Sumac (Real Time PCR)
도 6 내지 도 7에서 Real Time PCR을 수행한 결과 positive 인자인 Type 1 Collagen 과 Type 2 Collagen 및 Aggrecan의 경우 100ug/ml 농도에서 collagen과 aggrecan의 생성정도가 증가하는 것으로 보이며, 콜라겐보다 aggrecan에서 샘플효과가 더 잘 나타나는 것을 확인되었다.
As a result of performing Real Time PCR in FIGS. 6 to 7, the positive factors,
또한, 도 8 내지 도 9에서 Negative 인자인 MMPs 측정결과 역시 H2O2만 처리한 NC(Negative Control)에 비해서 옻나무 열수추출물 샘플을 처리한 군에서 MMPs의 감소가 나타난 것으로 보였다. 특히 100ug/ml 농도에서 MMP3과 MMP7의 감소하는 경향이 뚜렷하게 나타났다.
In addition, the results of the measurement of MMPs, which are Negative factors in FIGS. 8 to 9, also showed a decrease in MMPs in the group treated with Sumac hot water extract samples compared to NC (Negative Control) treated with H 2 O 2 only. In particular, the tendency of MMP3 and MMP7 to decrease at a concentration of 100ug / ml was obvious.
3. 실험결과 23.
본 발명은 옻나무 열수추출물의 분획을 통해 연골세포사멸 억제에 대한 in vitro 효능평가를 수행한 것으로 관절염에 효과가 있는 생리활성 물질을 분리, 동정할 수 있다.The present invention is to perform the in vitro efficacy evaluation on the inhibition of chondrocyte death through the fraction of the lacquer hot water extract can isolate and identify the bioactive substances effective for arthritis.
우선적으로 실험에 사용될 적정용량을 MTT cytotocixity assay를 통해 모두 300 μg/ml로 결정하여 세포에 처리하였고 세포독성은 H2O2를 이용하여 유도하였다. First, the appropriate dose to be used in the experiment was determined to 300 μg / ml all by MTT cytotocixity assay and treated to cells, and cytotoxicity was induced using H 2 O 2 .
옻나무 열수추출물 분획에서 세포의 독성은 없는 것으로 확인되었고, H2O2 처리후 유의적 사멸억제효과가 있었으며 300 μg/ml 농도에서 가장 효과적인 것으로 나타났다.It was found that there was no cell toxicity in the lacquer hot water extract fraction, and there was a significant killing effect after H 2 O 2 treatment and it was most effective at 300 μg / ml concentration.
연골세포 활성 평가 결과에 따르면 전반적으로 세포로의 유입이 나타나는 것으로 보이며 옻나무 열수 추출물의 200ug/ml의 농도에서 가장 높은 세포 유입이 확인되었다. According to the results of the chondrocyte activity evaluation, the inflow into the cells appeared generally, and the highest cell inflow was confirmed at the concentration of 200 ug / ml of the lacquer hot water extract.
또한, 세포수준에서의 유전자 발현에 관한 실험(Real-Time PCR)을 통해 골관절염의 측정지표인 Collagen과 MMPs의 발현 양상을 확인한 결과 옻나무 추출물 농도 100ug/ml에서 가장 효과가 있는 것으로 나타났다.In addition, the expression of collagen and MMPs, which are indicators of osteoarthritis, was shown to be most effective at 100 ug / ml of lacquer extract.
이는 앞서 시행한 세포독성시험과 항산화보호 효과 실험결과에서 가장 좋았던 300ug/ml의 농도 보다는 조금 낮게 나타난 결과이다. This is slightly lower than the concentration of 300 ug / ml, which was the best in the previous cytotoxicity test and the antioxidant protective effect test.
그러나 이 결과는 세포 자체의 사멸보다 유전자수준에서의 발현정도를 고려할 때, 직접 세포에서 실험했을때 보다는 조금 더 낮은 농도에서 긍정적인 효과를 기대할 수 있다.However, this result can be expected to have a positive effect at a slightly lower concentration than in the direct cell experiment, considering the expression level at the gene level rather than the death of the cell itself.
결론적으로, 세포수준에서의 실험결과로 볼 때 옻나무 추출물 분획이 골형성을 통한 골밀도 강화에 효과가 있는 것으로 확인되었으며 골관절염에 긍정적인 영향을 제공한다.
In conclusion, the experimental results at the cellular level confirmed that the lacquer extract fractions were effective in strengthening bone mineral density through bone formation and provide a positive effect on osteoarthritis.
이상의 본 발명은 상기에 기술된 실시예들에 의해 한정되지 않고, 당업자들에 의해 다양한 변형 및 변경을 가져올 수 있으며, 이는 첨부된 청구항에서 정의되는 본 발명의 취지와 범위에 포함된다.The invention being thus described, it will be obvious that the same way may be varied in many ways. Such modifications are intended to be within the spirit and scope of the invention as defined by the appended claims.
Claims (4)
A composition for the prevention and treatment of degenerative arthritis containing lacquer extract obtained by dipping C1-4 lower alcohol, alcohol alcohol, acetone extract or hot water extraction of lacquer tree with C1-4 lower alcohol and alcohol alcohol.
옻나무 열수 추출물로 분획된 C15H12O6(분자량 288)이며 백색의 결정체를 갖는 푸스틴(3,3',4',7-tetrahydroxyflavanone), C15H10O6(분자량 286)이며 황색의 결정체를 갖는 피세틴(Fisetin; 3,3',4',7-Tetrahydroxyflavone), C15H10O5(분자량 272)이며 진한 오렌지색의 결정체를 갖는 설푸레틴(Sulfuretin; 3',4',6'-Trihydroxyaurone), C15H12O5(분자량 272)이며 오렌지색의 결정체를 갖는 부테인(Butein; 2',3,4,4'-Tetrahydroxychalcone), C15H12O5(분자량 272)인 Garbanzol, C15H10O7(분자량 302)인 Quercetin, C15H10O5(분자량 270)인 5-deoxykaempferol, C6H6O2(분자량 110)인 Resorcino, C7H6O4(분자량 154)인 3,4-Benzoic acid, C7H6O4(분자량 154)인 2,4-Benzoic acid, C7H6O5(분자량 170)인 Gallic acid, C9H8O4(분자량 180)인 Caffeic acid, C9H11O4N5(분자량 253)인 Adenosin 또는 C6H5O2N(분자량 123)인 Niacin의 단일성분물질을 포함하여 구성된 것을 특징으로 옻나무 추출물을 함유하는 퇴행성 관절염의 예방 및 치료용 조성물
The method of claim 1,
C 15 H 12 O 6 (molecular weight 288), fractionated from P. lacquer extract, Fustine (3,3 ', 4', 7-tetrahydroxyflavanone) with white crystals, C 15 H 10 O 6 (molecular weight 286), yellow Fisetin (3,3 ', 4', 7-Tetrahydroxyflavone) with crystals of C 15 H 10 O 5 (molecular weight 272) and dark orange crystals Sulfuretine (3 ', 4', 6'-Trihydroxyaurone), C 15 H 12 O 5 (molecular weight 272) and orange crystals Butene (2 ', 3,4,4'-Tetrahydroxychalcone), C 15 H 12 O 5 (molecular weight 272) Garbanzol, C 15 H 10 O 7 (molecular weight 302) Quercetin, C 15 H 10 O 5 (molecular weight 270) 5-deoxykaempferol, C 6 H 6 O 2 (molecular weight 110) Resorcino, C 7 H 6 O 4 (molecular weight 154) in 3,4-Benzoic acid, C 7 H 6 O 4 ( molecular weight of 154) of 2,4-Benzoic acid, C 7 H 6 O 5 ( molecular weight 170) of Gallic acid, C 9 H 8 O 4 Single component of Caffeic acid (molecular weight 180), Adenosin with C 9 H 11 O 4 N 5 (molecular weight 253) or Niacin with C 6 H 5 O 2 N (molecular weight 123) A composition for the prevention and treatment of degenerative arthritis containing sumac extract, comprising the vagina
상기 조성물은 통상의 제조 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탄액, 에멀젼, 시럽, 에어로졸의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화할 수 있는 것을 특징으로 하는 옻나무 추출물을 함유하는 퇴행성 관절염의 예방 및 치료용 조성물
The method of claim 1,
The composition may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, oral formulations of aerosols, external preparations, suppositories, and sterile injectable solutions according to conventional preparation methods. Composition for the prevention and treatment of degenerative arthritis containing extract
Fustine (3,3 ', 4', 7-tetrahydroxyflavanone) and C 15 H 10 O 6 (C 15 H 12 O 6 (molecular weight 288) fractionated from the lacquer hydrothermal extract according to claim 1) Fistin (3,3 ', 4', 7-Tetrahydroxyflavone) with yellow crystals, molecular weight 286), C 15 H 10 O 5 (molecular weight 272) and Sulfurintin with dark orange crystals (3) ', 4', 6'-Trihydroxyaurone), C 15 H 12 O 5 (molecular weight 272) and orange crystals Butene (2 ', 3,4,4'-Tetrahydroxychalcone), C 15 H 12 O Garbanzol with 5 (molecular weight 272), Quercetin with C 15 H 10 O 7 (molecular weight 302), 5-deoxykaempferol with C 15 H 10 O 5 (molecular weight 270), Resorcino, C 6 H 6 O 2 (molecular weight 110) 7 H 6 O 4 (molecular weight of 154) of 3,4-Benzoic acid, C 7 H 6 O 4 ( molecular weight of 154) of 2,4-Benzoic acid, C 7 H 6 O 5 ( molecular weight 170) of Gallic acid, C 9 H 8 O 4 (molecular weight 180) of Caffeic acid, C 9 H 11 O 4 N 5 of the (molecular weight 253) of Adenosin, C 6 H 5 O 2 N ( molecular weight 123) Niacin One for the improvement of osteoarthritis containing sumac extract, characterized in that the active ingredient of the component material obtained by mixing and allowed acceptable carrier by an ordinary health food as the active ingredient dietary supplement
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120004226A KR20130083570A (en) | 2012-01-13 | 2012-01-13 | A composition comprising an extract of rhus vernicifluastokes for the prevention and treatment of arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120004226A KR20130083570A (en) | 2012-01-13 | 2012-01-13 | A composition comprising an extract of rhus vernicifluastokes for the prevention and treatment of arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20130083570A true KR20130083570A (en) | 2013-07-23 |
Family
ID=48994549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120004226A Ceased KR20130083570A (en) | 2012-01-13 | 2012-01-13 | A composition comprising an extract of rhus vernicifluastokes for the prevention and treatment of arthritis |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20130083570A (en) |
-
2012
- 2012-01-13 KR KR1020120004226A patent/KR20130083570A/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ansori et al. | Medicinal properties of Muntingia calabura L.: A Review | |
| Czerwińska et al. | The influence of procyanidins isolated from small-leaved lime flowers (Tilia cordata Mill.) on human neutrophils | |
| KR20160014707A (en) | Compositions and methods for joint health | |
| JP2012516842A (en) | Compositions from Sfaransus indicus and Garcinia mangostana for the suppression of metabolic syndrome | |
| Ahmad et al. | Peperomia pellucida (L.) Kunth herbs: A comprehensive review on phytochemical, pharmacological, extraction engineering development, and economic promising perspectives | |
| EP3204028A2 (en) | Synergistic composition for osteoarthritis | |
| Thao et al. | A Comparative study on polyphenol, flavonoid content, antioxidant and antiinflammatory capacity of different solvent extract from Portulaca oleracea in carrageenan-induced paw edema in mice | |
| KR100834850B1 (en) | Combination herbal composition with anti-allergic rhinitis, anti-atopic dermatitis or anti-chronic asthma effect | |
| Jain et al. | In–Vivo Antioxidant activity of ethanolic extract of Mentha pulegium leaf against CCl4 induced toxicity in rats | |
| Arshad et al. | Metabolite profiling of Cycas revoluta leaf extract and docking studies on alpha-glucosidase inhibitory molecular targets by phytochemicals | |
| Hasan | Antiarthritic efficacy of Clematis orientalis | |
| KR100711028B1 (en) | Obesity and type 2 diabetes prevention and treatment composition comprising juniper extract or cedrol | |
| Sweidan et al. | Therapeutic potential of Silybum marianum and Pergularia tomentosa extracts from Jordanian origin in diabetes mellitus | |
| KR102024188B1 (en) | Antiallergic composition comprising Allomyrina dichotoma larva extract | |
| Singh et al. | Evaluation of in-vitro antioxidant potential and in-vivo hepatoprotective activity of root extract of Quercus oblongata D. DON | |
| KR20130040663A (en) | A composition for improving or preventing a hyperlipemia and fatty liver comprising rhus verniciflua stokes | |
| Szypuła et al. | Biology, phytochemistry, pharmacology, and biotechnology of European ferns, club mosses, and horsetails: a review | |
| Osifo et al. | Wound healing and anti-inflammatory activities of Ceiba pentendra (l.) Gaertn | |
| KR20120080678A (en) | Composition for treatment of leukemia comprising extract of buddleiae flos | |
| Kamaei et al. | Comparison of antidiabetic effects of aqueous extract of the leaves and fruits of avicennia marina in streptozotocin-induced diabetic male rats | |
| KR20130083570A (en) | A composition comprising an extract of rhus vernicifluastokes for the prevention and treatment of arthritis | |
| Yosri et al. | Evaluation of Pleotropic Protective Activity of Capparis spinose Extract on Arthritis Rat Model | |
| KR20040008975A (en) | Composition having brain function and congnition enhancing activity | |
| KR100646078B1 (en) | Composition for the Prevention and Treatment of Degenerative Cranial Nerve Diseases Containing Orchard Extract | |
| KR100481684B1 (en) | Preventives and remedies of neurodegenerative disease containing pinusolide derivatives as active ingredients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20120113 |
|
| PA0201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130715 Patent event code: PE09021S01D |
|
| PG1501 | Laying open of application | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20140227 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20130715 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |